CervoMed to present neflamapimod biomarker and baseline data at CTAD; topline RewinD-LB due Dec 2024

CervoMed Inc.

Two late-breaking oral presentations at CTAD in Madrid (Oct 29 – Nov 1) on neflamapimod for DLB.
Plasma biomarker data from AscenD-LB Phase 2a study will be presented November 1.
Baseline data from RewinD-LB Phase 2b study to be featured; CEO says increases confidence in positive outcome.
Topline data from RewinD-LB Phase 2b study expected in December 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.